Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review.

[1]  Nelson B Rodrigues,et al.  The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. , 2020, Journal of affective disorders.

[2]  W. Drevets,et al.  Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) , 2020, The international journal of neuropsychopharmacology.

[3]  Xiang Li,et al.  Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). , 2020, The Journal of clinical psychiatry.

[4]  B. Kuehn.  Rising Emergency Department Visits for Suicidal Ideation and Self-harm. , 2020, JAMA.

[5]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[6]  Meng Li,et al.  A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. , 2019, Journal of affective disorders.

[7]  E. Brown,et al.  Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. , 2019, Journal of affective disorders.

[8]  L. Brådvik.  Suicide Risk and Mental Disorders , 2018, International journal of environmental research and public health.

[9]  S. Bachmann.  Epidemiology of Suicide and the Psychiatric Perspective , 2018, International journal of environmental research and public health.

[10]  W. Drevets,et al.  Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. , 2018, The American journal of psychiatry.

[11]  R. Shelton,et al.  Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial , 2017, JAMA psychiatry.

[12]  J. Mann,et al.  Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. , 2017, The American journal of psychiatry.

[13]  E. Ballard,et al.  Active suicidal ideation during clinical antidepressant trials , 2017, Psychiatry Research.

[14]  E. Ballard,et al.  The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. , 2017, The American journal of psychiatry.

[15]  Katharine A Smith,et al.  Lithium and suicide in mood disorders: Updated meta‐review of the scientific literature , 2017, Bipolar disorders.

[16]  J. Mann,et al.  Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam‐controlled randomized clinical trial , 2017, Bipolar disorders.

[17]  L. Gutiérrez-Rojas,et al.  Use of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain , 2017, Therapeutic advances in psychopharmacology.

[18]  Trina E. Chang,et al.  Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation , 2017, The Australian and New Zealand journal of psychiatry.

[19]  T. Stijnen,et al.  Suicidal ideation and subsequent completed suicide in both psychiatric and non-psychiatric populations: a meta-analysis , 2016, Epidemiology and Psychiatric Sciences.

[20]  Brian A Palmer,et al.  Continuation phase intravenous ketamine in adults with treatment-resistant depression. , 2016, Journal of affective disorders.

[21]  E. Brown,et al.  Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. , 2016, The Journal of clinical psychiatry.

[22]  R. McIntyre,et al.  A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect , 2016, Journal of clinical psychopharmacology.

[23]  J. Potash,et al.  Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. , 2015, The American journal of psychiatry.

[24]  W. Goodman,et al.  Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial , 2015, Psychological Medicine.

[25]  C. Galletly,et al.  Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression , 2015, The Australian and New Zealand journal of psychiatry.

[26]  N. Youssef,et al.  Ketamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature , 2015, Drugs in R&D.

[27]  H. Hinterhuber,et al.  The duration of the suicidal process: how much time is left for intervention between consideration and accomplishment of a suicide attempt? , 2009, The Journal of clinical psychiatry.

[28]  C. Reynolds,et al.  Ethical issues in including suicidal individuals in clinical research. , 2002, IRB.

[29]  F. Limosin,et al.  Ketamine Use for Suicidal Ideation in the General Hospital: Case Report and Short Review , 2018, Journal of psychiatric practice.

[30]  J. Kornhuber,et al.  Ketamine followed by memantine for the treatment of major depression. , 2008, The Australian and New Zealand journal of psychiatry.

[31]  Alan I Green,et al.  Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). , 2003, Archives of general psychiatry.